Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Investors to Inquire about Securities Investigation

Stock Information for Capricor Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Capricor Therapeutics Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.